Caterpillar bids for Australia’s RPMGlobal- AFR
CAMBRIDGE, UK—Alethia Young, the Chief Financial Officer of Bicycle Therapeutics PLC (NASDAQ:BCYC), recently sold a portion of her holdings in the company. According to a filing with the Securities and Exchange Commission, Young sold 215 ordinary shares on April 2, 2025, at a weighted average price of $8.02 per share, amounting to a total transaction value of $1,724. The transaction comes as the stock trades near its 52-week low, having declined about 67% over the past year.
This transaction was executed as part of a mandated "sell to cover" arrangement to satisfy statutory tax withholding obligations related to the vesting of restricted stock units. Post-transaction, Young retains ownership of 45,390 shares in the company. According to InvestingPro data, analysts maintain a bullish outlook on BCYC, with price targets ranging from $13 to $42.
Bicycle Therapeutics, a biotechnology company specializing in the development of novel therapies, is headquartered in Cambridge, UK. The company maintains strong liquidity with a current ratio of 13.8, though InvestingPro analysis indicates the stock is currently undervalued. For deeper insights and additional ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro, covering this and 1,400+ other US equities.
In other recent news, Bicycle Therapeutics reported promising results from its Phase 1 trial of zelenectide pevedotin, showing significant anti-tumor activity in patients with metastatic urothelial cancer. The trial revealed a 65% overall response rate without severe treatment-related adverse events. Bicycle Therapeutics is advancing its clinical pipeline, with plans to initiate Phase 1/2 trials for zelenectide pevedotin in various cancers in 2025. Financially, the company maintains a strong position with approximately $880 million in cash, expected to support operations into the second half of 2027. JMP Securities reaffirmed a Market Outperform rating with a $26 price target, while Jefferies adjusted its price target to $42, maintaining a Buy rating. Rodman & Renshaw also maintained a Buy rating with a $33 target, reflecting confidence in the company’s ongoing trials and financial stability. Additionally, Bicycle Therapeutics announced leadership changes, appointing Felix J. Baker as the new chairman and making several key promotions to enhance its oncology focus. These developments underscore the company’s strategic efforts to advance its oncology research and development initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.